Trial Profile
Phase II Single Arm Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Isatuximab (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- Acronyms ISAMAR
- 29 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Primary endpoint (Overall response ( partial response)) has been met, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results (n=61; 02/2017-10/2022) assessing the efficacy and safety of isatuximab with or without lenalidomide in patients with high risk smoldering multiple myeloma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.